Pilot Study of NASHA/Dx Gel for Fecal Incontinence

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Uppsala University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Uppsala University Hospital
ClinicalTrials.gov Identifier:
NCT00971269
First received: September 2, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted

September 2, 2009
September 2, 2009
January 2009
December 2010   (final data collection date for primary outcome measure)
Change in fecal incontinence episodes [ Time Frame: Follow up during a four week period and after 6 and 12 months ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Side effects related to treatment [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Pilot Study of NASHA/Dx Gel for Fecal Incontinence
A Pilot Study of Intersphincteric Injection of NASHA/Dx Gel for Fecal Incontinence

The study is an open, prospective, single-site study where 16 patients suffering from fecal incontinence will be included. Change in fecal incontinence episodes after intersphincteric injection of NASHA/Dx gel 4x2 ml and retreatment 4x2 ml after 4 weeks will be measured.

Not Provided
Interventional
Phase 1
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Fecal Incontinence
Device: Solesta (Nasha/Dx)
Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
Other Name: Solesta
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
16
June 2011
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Fecal incontinence with at least 2 episodes/week
  2. Symptom duration at least one year
  3. Failed attempt of conservative therapy
  4. Age 18-80
  5. Written informed consent
  6. Available for follow-up
  7. Fully compliant with protocol

Exclusion Criteria:

  1. Active inflammatory bowel disease
  2. Total external sphincter defect at ultrasound and clinical examination
  3. Bleeding diathesis or anticoagulant therapy
  4. Rectal prolapse or intussusceptions
  5. Present anal sepsis
  6. Anorectal implants
  7. Recent anorectal surgery (within 6 months)
  8. Rectal anastomosis
  9. Pregnancy, postpartum (one year) or breast feeding
Both
18 Years to 80 Years
No
Contact: Wilhelm JR Graf, MD PhD +46(0)18 611 46 06 wilhelm.graf@akademiska.se
Sweden
 
NCT00971269
EPN 2008/066
No
Professor Wilhelm Graf, Dept of Surgery, Uppsala University Hospital
Uppsala University Hospital
Not Provided
Not Provided
Uppsala University Hospital
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP